Table of Contents
Table of Contents
Preface
Chapter 1. From the Factory to the Frontlines: The Operation Warp Speed Strategy for Distributing a COVID-19 Vaccine
(U.S. Department of Health and Human Services)
Chapter 2. Explaining Operation Warp Speed
(U.S. Department of Health & Human Services)
Chapter 3. Trump Administration Expands Manufacturing Capacity with Cytiva for Components of COVID
(U.S. Department of Health & Human Services)
Chapter 4 Development and Regulation of Medical Countermeasures for COVID-19 (Vaccines, Diagnostics, and Treatments): Frequently Asked Questions
(Agata Dabrowska, Amanda K. Sarata, Frank Gottron and Kavya Sekar)
Chapter 5. Testing, Testing, (Phase) 1-2-3: Legal Considerations for Clinical Trials of Potential COVID-19 Vaccines
(Erin H. Ward)
Chapter 6. COVID-19 Vaccine Development
(United States Government Accountability Office)
Chapter 7. COVID-19: Legal Considerations for Bringing a New Vaccine to Market
(Erin H. Ward)
Chapter 8. Legal Issues in COVID-19 Vaccine Development
(Kevin J. Hickey and Erin H. Ward)
Chapter 9. Vaccine Safety in the United States: Overview and Considerations for COVID-19 Vaccines
(Kavya Sekar and Agata Dabrowska)
Chapter 10. Vaccine Safety
(CDC)
Chapter 11. Global Vaccination: Trends and U.S. Role
(Sara M. Tharakan)
Chapter 12. An Overview of State and Federal Authority to Impose Vaccination Requirements
(Wen W. Shen)
Chapter 13. Mitigating the Impact of Pandemic Influenza through Vaccine Innovation
(The Council of Economic Advisers)
Chapter 14. Influenza (Flu) Vaccine (Inactivated or Recombinant): What you need to know
(U.S. Department of Health and Human Services)
Chapter 15. Foot and Mouth Disease and Vaccine Use
(United States Department of Agriculture)
Chapter 16. Opioid Vaccines
(United States Government Accountability Office)
Index
